{
    "clinical_study": {
        "@rank": "166373", 
        "acronym": "NOBO", 
        "arm_group": [
            {
                "arm_group_label": "functional oil", 
                "arm_group_type": "Experimental", 
                "description": "Treatment consisted of consuming 5 ml of functional oil [olive oil (4 ml) with omega 3 fatty acids from fish oil (1 ml: 90% omega 3: 75-80% DHA and 10-15%  EPA) Orange flavour] during the day by 8 weeks."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Treatment consisted of consuming 5 ml of olive oil during the day by 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "Examine the effects and safety of functional oil (olive oil with omega 3 fatty acids from\n      fish oil) on different inflammatory markers in obese subjects with dietary intervention for\n      weight lost."
        }, 
        "brief_title": "Health Benefits of Functional Oil (Mega 3 Fatty Acids From Fish Oil) on Obese People", 
        "completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "condition": "Obesity", 
        "condition_browse": {
            "mesh_term": "Obesity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and women from 30 to 75 years old.\n\n          -  Body mass index (BMI) \u2265 30 kg/m2\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Individuals with special diet due to disease as celiac disease, chronic renal\n             failure, etc.\n\n          -  Individuals with Diabetes Mellitus insulin dependent.\n\n          -  Individuals with disorders associated with eating behaviour.\n\n          -  Individuals with mental disease or low cognitive function.\n\n          -  Individuals with consumption of drugs to weight lost.\n\n          -  Individuals treated with drugs whose direct effect is on lipid profile (statins,\n             fibrates, diuretics, corticosteroids or oral anti-inflammatory).\n\n          -  Individuals with diseases that could be involucrate in weight lost (not controlled\n             hypothyroidism, serious psychiatric illness, etc.)\n\n          -  Pregnant women or lactating.\n\n          -  Individuals with recurrent infections.\n\n          -  Individuals with regular consumption of anti-inflammatory or glucocorticoids.\n\n          -  Individuals with consumption of oil fish supplements (except if they gave up its\n             consumption 1 month before).\n\n          -  Individuals with fish allergy.\n\n          -  Individuals with consumption of more than two fatty fish servers twice a week.\n\n          -  Individuals with physical problems complying with the recommendations of physical\n             activity and diet indicated."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "52", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01739998", 
            "org_study_id": "NOBO"
        }, 
        "intervention": [
            {
                "arm_group_label": "functional oil", 
                "intervention_name": "functional oil", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 29, 2012", 
        "number_of_arms": "2", 
        "official_title": "Randomized, Double-blind, Controlled Study to Evaluate the Efficacy of Omega 3 Fatty Acids on Different Inflammatory Markers in Obese Subjects With Dietary Intervention for Weight Lost", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Spain: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Inflammatory markers (Adiponectin, fibrinogen, TNF\u03b1, PAI-1 and PCR", 
            "measure": "Inflammatory markers", 
            "safety_issue": "Yes", 
            "time_frame": "2 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01739998"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Parameters measured were: Weight, Height and waist circumference, muscle mass percentage (MM%), fat mass percentage (FM%).", 
                "measure": "Anthropometric parameters", 
                "safety_issue": "No", 
                "time_frame": "0.1 and 2 months"
            }, 
            {
                "description": "Parameters measured were: Cholesterol, LDL-Cholesterol, HDL-Cholesterol, Triglycerides, ApoB, ApoA1 and plasma free fatty acids.", 
                "measure": "Lipid profile", 
                "safety_issue": "No", 
                "time_frame": "0.1 and 2 months"
            }, 
            {
                "description": "Parameters measured were: Leptin and ghrelin", 
                "measure": "Hormonal Parameters", 
                "safety_issue": "No", 
                "time_frame": "0.2 months"
            }, 
            {
                "description": "Parameters measured were: plasma antioxidant capacity (FRAP, ferric reducing antioxidant power) and lipidic peroxidation (TBARS, thiobarbituric acid reactive substances assay).", 
                "measure": "Oxidative Stress Parameters", 
                "safety_issue": "Yes", 
                "time_frame": "0 and 2 months"
            }, 
            {
                "description": "Parameters measured were: glucose, basal insulin, HbA1c (in diabetic patients), HOMA index (glucemic insulin sensitivity index was calculated using the formula: HOMA-IR = fasting glucose (mmol/l)/fasting immunoreactive insulin (mU/ml)/22\u20225).", 
                "measure": "Glucosa Metabolism", 
                "safety_issue": "Yes", 
                "time_frame": "0, 1 and 2 months"
            }, 
            {
                "description": "Parameters measured were: Beck Depression Inventory (BDI).", 
                "measure": "Depression Test", 
                "safety_issue": "No", 
                "time_frame": "0 and 2 months"
            }, 
            {
                "description": "Parameters measured were: Visual analogue scale to assess motivation and satiety to eat.", 
                "measure": "Motivation and Satiety Parameters", 
                "safety_issue": "No", 
                "time_frame": "0 and 2 month"
            }, 
            {
                "description": "Questionnaire of adherence and tolerance to the product.", 
                "measure": "Adeherence and Tolerance parameters", 
                "safety_issue": "No", 
                "time_frame": "up to 2 months"
            }
        ], 
        "source": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Instituto de Investigaci\u00f3n Hospital Universitario La Paz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "November 2012"
    }
}